RBC rates Alphatec at outperform

Alphatec Spine, Inc. was rated at outperform, above average risk, by RBC Capital Markets analyst William R. Quirk, who believes the company's rapid distribution expansion and product ramp-ups, coupled with its service, differentiate it from competitors. Alphatec could deliver year-over-year growth of plus 90% in 2006. Shares of the Carlsbad, Calif.-based medical device company were down 16 cents, or 2.69%, at $5.78 on volume of 30,653 shares versus the three-month running average of 77,239 shares. (Nasdaq: ATEC)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.